Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
2 Adipocytokine signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
3 Adipocytokine signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
4 African trypanosomiasis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
5 African trypanosomiasis 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
6 African trypanosomiasis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
7 African trypanosomiasis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
8 African trypanosomiasis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
12 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
14 Alcoholic liver disease 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
15 Alcoholic liver disease 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
16 Alcoholic liver disease 💬
 1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
17 Alcoholic liver disease 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
18 Alcoholic liver disease 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
19 Alcoholic liver disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
20 Alcoholic liver disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
21 Alcoholic liver disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
22 Allograft rejection 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
23 Allograft rejection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
24 Allograft rejection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
25 Alzheimer disease 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
26 Alzheimer disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
27 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
28 Alzheimer disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
29 Alzheimer disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
30 Amoebiasis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
31 Amoebiasis 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
32 Amoebiasis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
33 Amoebiasis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
34 Amoebiasis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
35 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
36 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
37 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
38 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
39 Antifolate resistance 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
40 Antifolate resistance 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
41 Antifolate resistance 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
42 Antifolate resistance 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
43 Antigen processing and presentation 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
44 Antigen processing and presentation 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
45 Apoptosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
46 Apoptosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
47 Asthma 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
48 Asthma 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
49 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
50 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
51 C-type lectin receptor signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
52 C-type lectin receptor signaling pathway 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
53 C-type lectin receptor signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
54 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
55 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
56 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
57 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
58 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
59 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
60 Chagas disease 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
61 Chagas disease 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
62 Chagas disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
63 Chagas disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
64 Chagas disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
65 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
66 Chemokine signaling pathway 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
67 Cholinergic synapse 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
68 Complement and coagulation cascades 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
69 Coronavirus disease - COVID-19 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
70 Coronavirus disease - COVID-19 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
71 Coronavirus disease - COVID-19 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
72 Coronavirus disease - COVID-19 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
73 Coronavirus disease - COVID-19 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
74 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
75 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
76 Cytokine-cytokine receptor interaction 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
77 Cytokine-cytokine receptor interaction 💬
 1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
78 Cytokine-cytokine receptor interaction 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
79 Cytokine-cytokine receptor interaction 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
80 Cytokine-cytokine receptor interaction 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
81 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
82 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
83 Cytosolic DNA-sensing pathway 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
84 Cytosolic DNA-sensing pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
85 Dilated cardiomyopathy 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
86 Dilated cardiomyopathy 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
87 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
88 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
89 Epstein-Barr virus infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
90 Epstein-Barr virus infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
91 Epstein-Barr virus infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
92 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
93 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
94 Fluid shear stress and atherosclerosis 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
95 Fluid shear stress and atherosclerosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
96 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
97 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
98 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
99 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
100 Graft-versus-host disease 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
101 Graft-versus-host disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
102 Graft-versus-host disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
103 Graft-versus-host disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
104 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
105 Hematopoietic cell lineage 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
106 Hematopoietic cell lineage 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
107 Hematopoietic cell lineage 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
108 Hematopoietic cell lineage 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
109 Hepatitis B 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
110 Hepatitis B 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
111 Hepatitis B 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
112 Hepatitis C 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
113 Hepatitis C 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
114 Hepatitis C 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
115 Herpes simplex virus 1 infection 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
116 Herpes simplex virus 1 infection 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
117 Herpes simplex virus 1 infection 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
118 Herpes simplex virus 1 infection 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
119 Herpes simplex virus 1 infection 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
120 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
121 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
122 Human cytomegalovirus infection 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
123 Human cytomegalovirus infection 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
124 Human cytomegalovirus infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
125 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
126 Human cytomegalovirus infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
127 Human cytomegalovirus infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
128 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
129 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
130 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
131 Human papillomavirus infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
132 Human papillomavirus infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
133 Human papillomavirus infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
134 Human T-cell leukemia virus 1 infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
135 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
136 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
137 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
138 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
139 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
140 IL-17 signaling pathway 💬
 1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
141 IL-17 signaling pathway 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
142 IL-17 signaling pathway 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
143 IL-17 signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
144 IL-17 signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
145 IL-17 signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
146 Inflammatory bowel disease 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
147 Inflammatory bowel disease 💬
 1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
148 Inflammatory bowel disease 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
149 Inflammatory bowel disease 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
150 Inflammatory bowel disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
151 Inflammatory bowel disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
152 Inflammatory bowel disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
153 Inflammatory mediator regulation of TRP channels 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
154 Inflammatory mediator regulation of TRP channels 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
155 Influenza A 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
156 Influenza A 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
157 Influenza A 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
158 Influenza A 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
159 Influenza A 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
160 Influenza A 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
161 Insulin resistance 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
162 Insulin resistance 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
163 JAK-STAT signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
164 JAK-STAT signaling pathway 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
165 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
166 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
167 Legionellosis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
168 Legionellosis 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
169 Legionellosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
170 Legionellosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
171 Legionellosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
172 Leishmaniasis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
173 Leishmaniasis 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
174 Leishmaniasis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
175 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
176 Leishmaniasis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
177 Leishmaniasis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
178 Lipid and atherosclerosis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
179 Lipid and atherosclerosis 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
180 Lipid and atherosclerosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
181 Lipid and atherosclerosis 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
182 Lipid and atherosclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
183 Lipid and atherosclerosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
184 Lipid and atherosclerosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
185 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
186 Malaria 💬
 1件: IL12A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
187 Malaria 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
188 Malaria 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
189 Malaria 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
190 Malaria 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
191 MAPK signaling pathway 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
192 MAPK signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
193 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
194 MAPK signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
195 MAPK signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
196 Measles 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
197 Measles 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
198 Measles 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
199 Measles 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
200 mTOR signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
201 mTOR signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
202 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
203 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
204 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
205 Necroptosis 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
206 Necroptosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
207 Necroptosis 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
208 Necroptosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
209 Necroptosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
210 Neuroactive ligand-receptor interaction 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
211 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Prednisolone 💬 Prednisolone 42件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
212 Neutrophil extracellular trap formation 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
213 NF-kappa B signaling pathway 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
214 NF-kappa B signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
215 NF-kappa B signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
216 NF-kappa B signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
217 NOD-like receptor signaling pathway 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
218 NOD-like receptor signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
219 NOD-like receptor signaling pathway 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
220 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
221 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
222 Non-alcoholic fatty liver disease 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
223 Non-alcoholic fatty liver disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
224 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
225 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
226 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
227 Osteoclast differentiation 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
228 Osteoclast differentiation 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
229 Osteoclast differentiation 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
230 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
231 Osteoclast differentiation 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
232 Osteoclast differentiation 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
233 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
234 Pancreatic cancer 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
235 Pathogenic Escherichia coli infection 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
236 Pathogenic Escherichia coli infection 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
237 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
238 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
239 Pathways in cancer 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
240 Pathways in cancer 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
241 Pathways of neurodegeneration - multiple diseases 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
242 Pathways of neurodegeneration - multiple diseases 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
243 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
244 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
245 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
246 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
247 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
248 Pertussis 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
249 Pertussis 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
250 Pertussis 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
251 Pertussis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
252 Pertussis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
253 Pertussis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
254 PI3K-Akt signaling pathway 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
255 Prion disease 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
256 Prion disease 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
257 Prion disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
258 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
259 Prion disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
260 Prion disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
261 Prolactin signaling pathway 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
262 Proteoglycans in cancer 💬
 1件: IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
263 Proteoglycans in cancer 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
264 Proteoglycans in cancer 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
265 Regulation of actin cytoskeleton 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
266 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
267 Rheumatoid arthritis 💬
 1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
268 Rheumatoid arthritis 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
269 Rheumatoid arthritis 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
270 Rheumatoid arthritis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
271 Rheumatoid arthritis 💬
 1件: IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
272 Rheumatoid arthritis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
273 Rheumatoid arthritis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
274 RIG-I-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
275 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
276 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
277 Salmonella infection 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
278 Salmonella infection 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
279 Salmonella infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
280 Salmonella infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
281 Shigellosis 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
282 Shigellosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
283 Shigellosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
284 Shigellosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
285 Signaling pathways regulating pluripotency of stem cells 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
286 Sphingolipid signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
287 Sphingolipid signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
288 Staphylococcus aureus infection 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
289 Systemic lupus erythematosus 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
290 Systemic lupus erythematosus 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
291 Systemic lupus erythematosus 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
292 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
293 T cell receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
294 T cell receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
295 TGF-beta signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
296 TGF-beta signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
297 Th1 and Th2 cell differentiation 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
298 Th1 and Th2 cell differentiation 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
299 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
300 Th17 cell differentiation 💬
 1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
301 Th17 cell differentiation 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
302 Th17 cell differentiation 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
303 Th17 cell differentiation 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
304 Th17 cell differentiation 💬
 1件: IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
305 Th17 cell differentiation 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
306 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
307 TNF signaling pathway 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
308 TNF signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
309 TNF signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
310 TNF signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
311 Toll-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
312 Toll-like receptor signaling pathway 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
313 Toll-like receptor signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
314 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
315 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
316 Toxoplasmosis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
317 Toxoplasmosis 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
318 Toxoplasmosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
319 Toxoplasmosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
320 Tuberculosis 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
321 Tuberculosis 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
322 Tuberculosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
323 Tuberculosis 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
324 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
325 Tuberculosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
326 Tuberculosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
327 Type I diabetes mellitus 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
328 Type I diabetes mellitus 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
329 Type I diabetes mellitus 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
330 Type I diabetes mellitus 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
331 Type I diabetes mellitus 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
332 Type II diabetes mellitus 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
333 Type II diabetes mellitus 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
334 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
335 Viral carcinogenesis 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
336 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
337 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
338 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
339 Yersinia infection 💬
 1件: IL1B 💬 Canakinumab 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
340 Yersinia infection 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
341 Yersinia infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
342 Yersinia infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬

先頭へ